

Change of Registered Address & Principal Place of Business

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), advises that in accordance with ASX Listing Rule 3.14, the address of its registered office and its principal place of business will change, effective immediately.

The Company's new details will be, as follows:

Registered Address & Principal Place of Business:

Suite 102 / Level 1, 55 Collins Street,
Melbourne, VIC 3000

Phone number of Registered Office:

03 9498 3132

All other contact details remain unchanged.

Authority

This announcement was authorised for release by the Board of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.